The spectrum of statin therapy in cancer patients: is there a need for further investigation?

Abstract

Although our understanding of the relationship between cancer and statin use continues to improve, it remains a complex association requiring further research focusing on both biologic and clinical end points in a wide range of patient populations. To date, most of the published results are from observational studies detailing the risk of incident cancers or from randomized controlled trials with cardiovascular primary end points and cancer only as a secondary end point. Although there is certainly great value in the information obtained from observational studies, they cannot prove a causal link between statins and cancer, and it would then seem appropriate to design and implement clinical trials. Such studies should consider three main end products of the mevalonate pathway (cholesterol, geranyl pyrophosphate, and farnesyl pyrophosphate) from a mechanistic perspective, as well as the potential for cancer cell mediation with statin use, in addition to pertinent clinical end points including cancer incidence and mortality.

• Authors: Michael J Gonyeau
• Journal: Current atherosclerosis reports (Curr Atheroscler Rep) Vol. 16 Issue 1 Pg. 383 (Jan 2014) ISSN: 1534-6242 [Electronic] United States
• PMID: 24306898 (Publication Type: Journal Article, Review)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors

Topics

• Animals
• Clinical Trials as Topic
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Incidence
• Neoplasms (drug therapy, mortality)
• Risk
• Treatment Outcome